Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 6/20 | 0.71 |
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 7/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.65 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093979 | 1.00 | KCNMA1 (0.71) | KCNMA1TMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL330387 | 0.87 | KCNMA1 (0.81) | KCNMA1TMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL15026045 | 0.87 | KCNMA1 (0.76) | KCNMA1TMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL30771727 | 0.87 | KCNMA1 (0.76) | KCNMA1TMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL30887952 | 0.85 | KCNMA1 (0.59) | KCNMA1TMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL2167354 | 0.85 | KCNMA1 (0.59) | KCNMA1TMPRSS4P2RX1P2RX4P2RX7 | |
| SCHEMBL16139019 | 0.85 | RAB9A (0.65) | KCNMA1TMPRSS4P2RX1CYP1A2CYP2C19 | |
| SCHEMBL9901505 | 0.84 | CYP2C19 (0.72) | CYP1A2CYP2C19HPGDMEN1NPC1 | |
| SCHEMBL2701801 | 0.83 | HPGD (0.77) | KCNMA1CYP1A2CYP2C19HPGDMEN1 | |
| SCHEMBL733479 | 0.83 | ALDH1A1 (0.69) | CYP1A2CYP2C19HPGDKDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | claimed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | claimed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023149548-A1 | NOVEL PHARMACEUTICAL COMPOSITION | 国立大学法人富山大学 | 2023-08-10 | — | — | WO | disclosed |
| WO-2022109148-A1 | SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11331290-B2 | Niclosamide for the treatment of cancer metastasis | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20220125807-A1 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
| CN-101537001-A | Application of compound as JAK-STAT3 signal passage inhibitor | GUANGZHOU INST BIOMED & HEALTH | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | ACE2, ACE, TMPRSS2 | KCNMA1 3777/4885TMPRSS4 14/4885P2RX1 2669/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | KCNMA1 4847/4885TMPRSS4 2074/4885P2RX1 3423/4885 |
| US-11331290-B2 | Niclosamide for the treatment of cancer metastasis | S100A4, S100A11, S100A6 | KCNMA1 2446/4885TMPRSS4 22/4885P2RX1 3207/4885 |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | GLS2, PC, GLS | KCNMA1 2695/4885TMPRSS4 2431/4885P2RX1 1629/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KCNMA1 1417/4885TMPRSS4 2146/4885P2RX1 848/4885 |
| US-20220125807-A1 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS | S100A4, CTNNBL1, CTNNB1 | KCNMA1 2253/4885TMPRSS4 60/4885P2RX1 3492/4885 |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | STAT3, STAT1, STAT5A | KCNMA1 4668/4885TMPRSS4 849/4885P2RX1 3966/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNMA1 1478/4885TMPRSS4 2067/4885P2RX1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.